Now that the data is going to a 23andMe-adjacent nonprofit, which is also making similar promises, I guess nothing much has ...

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

Anne Wojcicki, founder and former CEO of 23andMe, will helm the company again after her nonprofit's purchase was approved.

Me Holding said Tuesday that a U.S. bankruptcy court has approved the sale of “substantially all” its assets to TTAM Research Institute, a California-based nonprofit led by company co-founder and ...

The consumer privacy ombudsman in 23andMe’s sale of customers’ genetic data is defending his choice of counsel against ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

A bankruptcy court approved the $305M sale of 23andMe to a nonprofit led by Anne Wojcicki, raising questions about data ...

The franchise drug for autoimmune disorders such as dermatitis could face a challenger: A candidate from Apogee Therapeutics.

Former 23andMe CEO Anne Wojcicki now runs TTAM Research Institute, which outbid Regeneron in an auction for the bankrupt company’s assets.

States with privacy objections to the sale have until July 7 to reach a stay to appeal the case. TTAM, a nonprofit started by ...

Former CEO Anne Wojcicki's nonprofit TTAM Research Institute will purchase “substantially all” of San Francisco-based 23andMe ...